MVision AI Wins South Korean Approval for Guideline-Based AI Segmentation Tech

South Korean regulators have greenlighted MVision AI’s image analysis algorithms for use in radiation therapy treatment planning workflows, enabling the company to introduce its AI Segmentation technology (Contour+) throughout the country.
 
Contour+ accelerates the image contouring process, provides guidance toward standardization, enhances consistency and saves time, as confirmed by independent evaluations^1-3 and customer experiences.⁴ MVision AI designed Contour+ to steer a clinic’s contouring practice towards consensus and guideline compliance.

“MVision AI and Energy Flow are thrilled to announce our GBS solution’s launch in South Korea. This will significantly reduce contouring time in oncology departments, ensuring standardized and efficient patient care,” MVision AI CEO Dharanipathy Rangaraj said. “Our training and validation tools will keep clinical teams updated on best practices. Being selected as the preferred vendor marks an important milestone for MVision as we expand beyond Europe and the U.S. The approval in South Korea underscores the effectiveness and potential of our technology. We are dedicated to providing the best possible care to cancer patients worldwide by making our solutions accessible to all radiation oncology professionals.”

In South Korea, cancer remains a major public health issue. A study published in Cancer Research and Treatment indicated the number of new cancer diagnoses increased 10.8% (27,002 cases) in 2021 compared to the previous year. Newly diagnosed cancer cases and deaths from cancer in 2021 were 277,523 (age-standardized rate [ASR], 289.3 per 100,000) and 82,688 (ASR, 67.6 per 100,000), respectively.⁵ 
 
“We would like to extend our gratitude to our distributor, Energy Flow, for their partnership in achieving this approval. Their support has been instrumental in navigating the regulatory landscape and bringing our innovative solutions to the South Korean market,” Rangaraj added.

MVision AI’s GBS solution enhances radiation oncology professionals’ expertise in AI contouring together with a robust Return On Investment (ROI) strategy. The solution contains three products: Contour+, Guide, and Verify. 
 
“The NCC is one of the most important radiation therapy centers in Korea, and it was also the first place to start proton therapy. The NCC already had a lot of experience with the Auto Contouring System, and it is very encouraging that MVision AI was chosen out of many of those experiences. This will mark the beginning of MVision AI’s record as being evaluated as the best product in the Korean market, taking the top market share,” Energy Flow Founder Young Lip Chung stated.
 
MVision AI provides artificial intelligence-powered solutions for radiation therapy treatment planning. 
 
Established in 2021, Energy Flow is a supplier specializing in radiation therapy devices. It currently supplies products to the Korean market from the IBA Proton system, Theragenics, and SGM. In addition, it has a nuclear safety consulting team for radiation therapy devices. The representatives are Chung and Dr. Ji, Young-Hoon, the expert member of the Ministry of Food and Drug Safety in Korea, who is the senior advisor. 
 
References
¹ MVision.ai – MVision AI Contour+ (Guideline-Based AI Segmentation): highlights from an independent validation study using a comprehensive and curated data set
² MVision.ai – Research Results of MVision AI Contour+ Models’ Clinical Evaluation
³ MVision.ai – NCCC Evaluation of MVision AI contouring software
⁴ MVision.ai – The voice of customer experience: Dr. Giuseppe Sasso, New Zealand
⁵ Eun Hye Park et al. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2021. Cancer Res Treat. 2024 Apr;56(2):357-371. doi: 10.4143/crt.2024.253. Epub 2024 Mar 13. PMID: 38487832 PMCID: PMC11016640.